Inflammation and prostate carcinogenesis

International Journal of Urology

Volumn 20, Issue 2, 2013, Pages 150-160

  Nakai, Yasutomo ^a   Nonomura, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Diet; Inflammation; Prostate cancer

Indexed keywords

2 AMINO 1 METHYL 6 PHENYLIMIDAZO[4,5 B]PYRIDINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME P450 1A2; GENOMIC DNA; GLUTATHIONE TRANSFERASE P1; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 2; PROSTACYCLIN; PROSTAGLANDIN; PROSTATE SPECIFIC ANTIGEN; THROMBOXANE;

ALCOHOL CONSUMPTION; ANCHORAGE INDEPENDENT GROWTH; ANDROGEN DEPRIVATION THERAPY; BACTERIUM CULTURE; CARCINOGENESIS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CHLAMYDIA TRACHOMATIS; CHRONIC INFLAMMATION; CORRELATION ANALYSIS; DIET; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; HUMAN; IMMUNOHISTOCHEMISTRY; MAST CELL; MEDICAL HISTORY; MORTALITY; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATITIS; REVIEW; SELF REPORT; SEROLOGY; SEXUALLY TRANSMITTED DISEASE; SMOKING; TRICHOMONAS VAGINALIS; UPREGULATION; UREAPLASMA UREALYTICUM; XENOTROPIC MULV RELATED VIRUS;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHRONIC DISEASE; COMORBIDITY; DIET; DISEASE-FREE SURVIVAL; ENVIRONMENT; EVIDENCE-BASED MEDICINE; HUMANS; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; PREVALENCE; PROGNOSIS; PROSTATIC NEOPLASMS; PROSTATITIS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 84873255566     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.03101.x     Document Type: Review

References (126)

1. Cook LS, Goldoft M, Schwartz SM, Weiss NS. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J. Urol. 1999; 161: 152-5.
2. Kolonel LN, Altshuler D, Henderson BE. The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nat. Rev. Cancer 2004; 4: 519-27.
3. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
4. Roberts RO, Bergstralh EJ, Bass SE, Lieber MM, Jacobsen SJ. Prostatitis as a risk factor for prostate cancer. Epidemiology 2004; 15: 93-9.
5. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002; 60: 78-83.
6. Daniels NA, Ewing SK, Zmuda JM etal. Correlates and prevalence of prostatitis in a large community-based cohort of older men. Urology 2005; 66: 964-70.
7. Niijima T, Koiso K. Incidence of prostatic cancer in Japan and Asia. Scand J. Urol. Nephrol. Suppl. 1980; 55: 17-21.
8. Mishina T, Watanabe H, Araki H etal. Epidemiological study of prostatic cancer by matched-pair analysis. Prostate 1985; 6: 423-36.
9. Honda GD, Bermstein L, Ross RK etal. Vasectomy, cigarette smoking, and age at first sexual intercourse as risk factors for prostate cancer in middle-aged men. Br. J. Cancer 1988; 57: 326-31.
10. Nakata S, Imai K, Yamanaka H. Study of risk factors for prostatic cancer. Acta Urol. Jpn. 1993; 39: 1017-25.
11. Hiatt RA, Armstrong MA, Klatsky AL etal. Alcohol consumption, smoking, and other risk factors and prostate cancer in a large health plan cohort in California (United Stages). Cancer Causes Control 1994; 5: 66: 72.
12. Zhu K, Stanford JL, Daling JR etal. Vasectomy and prostate cancer: a case-control study in a health maintenance organization. Am. J. Epidemiol. 1996; 15: 717-22.
13. Hayes RB, Pottern LM, Strickler H etal. Sexual behaviour, STDs and risks for prostate cancer. Br. J. Cancer 2000; 82: 718-25.
14. Roberts RO, Bergstralh EJ, Bass SE etal. Prostatitis as a risk for prostate cancer. Epidemiology 2004; 15: 93-9.
15. Patel DA, Bock CH, Scwartz K etal. Sexually transmitted diseases and other urogenital conditions as risk factors for prostate cancer: a case-control study in Wayne County, Michigan. Cancer Causes Control 2005; 16: 263-73.
16. Fernandez L, Galan Y, Jimenez R etal. Sexual behaviour, history of sexually transmitted diseases, and the risk of prostate cancer: a case-control study in Cuba. Int. J. Epidemiol. 2005; 34: 193-7.
17. Sutcliffe S, Giovannucci E, De Marzo AM etal. Gonorrhea, syphilis, clinical prostatitis, and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2006; 15: 2160-6.
18. Huang WY, Hayes R, Pfeiffer R etal. Sexually transmissible infections and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 2008; 17: 2374-81.
19. Cheng I, Witte, JS, Jacobsen SJ etal. Prostatitis, sexually transmitted diseases, and prostate cancer: the California Men's Health Study. PLoS One 2010; 15: e8736.
20. Palapattu GS, Sutcliffe S, Bastian PJ etal. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005; 26: 1170-81.
21. Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J. Urol. 2004; 171 (2 Pt 2): S36-40.
22. De Marzo AM, Platz EA, Epstein JI etal. A working group classification of focal prostate atrophy lesions. Am. J. Surg. Pathol. 2006; 30: 1281-91.
23. Franks LM. Atrophy and hyperplasia in the prostate proper. J. Pathol. Bacteriol. 1954; 68: 617-21.
24. Liavåg I. Atrophy and regeneration in the pathogenesis of prostatic carcinoma. Acta Pathol. Microbiol. Scand. 1968; 73: 338-50.
25. McNeal JE. Normal histology of the prostate. Am. J. Surg. Pathol. 1988; 12: 619-33.
26. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am. J. Pathol. 1999; 155: 1985-92.
27. Putzi MJ, De Marzo AM. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 2000; 56: 828-32.
28. Parsons JK, Nelson CP, Gage WR, Nelson WG, Kensler TW, Se Marzo AM. GSTA1 expression in normal, preneoplastic, and neoplastic human prostate tissue. Prostate 2001; 49: 30-7.
29. Lee WH, Morton RA, Epstein JI etal. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 1994; 91: 11733-7.
30. Nakayama M, Bennett CJ, Hicks JL etal. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am. J. Pathol. 2003; 163: 923-33.
31. Tsujimoto Y, Takayama H, Nonomura N, Okuyama A, Aozasa K. Postatrophic hyperplasia of the prostate in Japan: histologic and immunohistochemical features and p53 gene mutation analysis. Prostate 2002; 52: 279-87.
32. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA 1999; 282: 236-7.
33. Schaeffer AJ, Wendel EF, Dunn JK, Grayhack JT. Prevalence and significance of prostatic inflammation. J. Urol. 1981; 125: 215-19.
34. Krieger JN. Classification, epidemiology and implications of chronic prostatitis in North America, Europe and Asia. Minerva Urol. Nefrol. 2004; 56: 99-107.
35. Krieger JN, Ross SO, Riley DE. Chronic prostatitis: epidemiology and role of infection. Urology 2002; 60 (6 Suppl): 8-12.
36. Shimomura T, Kiyota H, Takahashi H, Madarame J, Kimura T, Onodera S. Prostate histopathology of NIH category IV prostatitis detected by sextant prostate needle biopsy from the patients with high prostatic specific antigen. Kansenshogaku Zasshi 2003; 77: 611-17.
37. Potts JM. Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen. J. Urol. 2000; 164: 1550-3.
38. Giovannucci E. Medical history and etiology of prostate cancer. Epidemiol. Rev. 2001; 23: 159-62.
39. Bozeman CB, Carver BS, Eastham JA, Venable DD. Treatment of chronic prostatitis lowers serum prostate specific antigen. J. Urol. 2002; 167: 1723-6.
40. Carver BS, Bozeman CB, Williams BJ, Venable DD. The prevalence of men with National Institutes of Health category IV prostatitis and association with serum prostate specific antigen. J. Urol. 2003; 169: 589-91.
41. Loeb S, Carter HB, Catalona WJ, Moul JW, Schroder FH. Baseline prostate-specific antigen testing at a young age. Eur. Urol. 2012; 61: 1-7.
42. Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 2002; 13: 72-9.
43. Taylor ML, Mainous AG III, Wells BJ. Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam. Med. 2005; 37: 506-12.
44. Hayes RB, Pottern LM, Strickler H etal. Sexual behavior, STDs and risks for prostate cancer. Br. J. Cancer 2000; 82: 718-25.
45. Anttila T, Tenkanen L, Lumme S etal. Chlamydial antibodies and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2005; 14: 385-9.
46. Dennis LK, Coughlin JA, McKinnon BC etal. Sexually transmitted infections and prostate cancer among men in the U.S. military. Cancer Epidemiol. Biomarkers Prev. 2009; 18: 2265-71.
47. Dillner J, Knekt P, Boman J etal. Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer. Int. J. Cancer 1998; 75: 564-7.
48. Hisada M, Rabkin CS, Strickler HD, Wright WE, Christianson RE, van den Berg BJ. Human papillomavirus antibody and risk of prostate cancer. JAMA 2000; 283: 340-1.
49. Strickler HD, Schiffman MH, Shah KV etal. A survey of human papillomavirus 16 antibodies in patients with epithelial cancers. Eur. J. Cancer Prev. 1998; 7: 305-13.
50. Rosenblatt KA, Carter JJ, Iwasaki LM, Galloway DA, Stanford JL. Serologic evidence of human papillomavirus 16 and 18 infections and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2003; 12: 763-8.
51. Sitas F, Carrara H, Beral V etal. Antibodies against human herpesvirus 8 in black South African patients with cancer. N. Engl. J. Med. 1999; 340: 1863-71.
52. Baker LH, Mebust WK, Chin TD, Chapman AL, Hinthorn D, Towle D. The relationship of herpesvirus to carcinoma of the prostate. J. Urol. 1981; 125: 370-4.
53. Herbert JT, Birkhoff JD, Feorino PM, Caldwell GG. Herpes simplex virus type 2 and cancer of the prostate. J. Urol. 1976; 116: 611-12.
54. Hoffman LJ, Bunker CH, Pellett PE etal. Elevated seroprevalence of human herpesvirus 8 among men with prostate cancer. J. Infect. Dis. 2004; 189: 15-20.
55. Sutcliffe S, Kawachi I, Alderete JF etal. Correlates of sexually transmitted infection histories in a cohort of American male health professionals. Cancer Causes Control 2009; 20: 1623-34.
56. Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garret KL. Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? J. Urol. 2005; 173: 1969-74.
57. Alexeyev O, Bergh J, Marklund I etal. Association between the presence of bacterial 16S RNA in prostate specimens taken during transurethral resection of prostate and subsequent risk of prostate cancer (Sweden). Cancer Causes Control 2006; 17: 1127-33.
58. Fassi Fehri L, Mak TN, Laube B etal. Prevalence of Propionibacterium acnes in diseased prostates and its inflammatory and transforming activity on prostate epithelial cells. Int. J. Med. Microbiol. 2011; 301: 69-78.
59. Sutcliffe S, Giovannucci E, Isaacs WB, Willett WC, Platz EA. Acne and risk of prostate cancer. Int. J. Cancer 2007; 121: 2688-92.
60. Giles GG, Severi G, English DR etal. Early growth, adult body size and prostate cancer risk. Int. J. Cancer 2003; 103: 241-5.
61. Lightfoot N, Conlon M, Kreiger N, Sass-Kortsak A, Purdham J, Darlington G. Medical history, sexual, and maturational factors and prostate cancer risk. Ann. Epidemiol. 2004; 14: 655-62.
62. Galobarrdes B, Davey Smith G, Jeffreys M, Kinra S, McCarron P. Acne in adolescence and cause-specific mortality: lower coronary heart disease but higher prostate cancer mortality: the Glasgow Alumni Cohort Study. Am. J. Epidemiol. 2005; 161: 1094-101.
63. Casey G, Neville PJ, Plummer SJ etal. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat. Genet. 2002; 32: 581-3.
64. Silverman RH. Implications for RNase L in prostate cancer biology. Biochemistry 2003; 42: 1805-12.
65. Urisman A, Molinaro RJ, Fischer N etal. Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog. 2006; 2: e25.
66. Schlaberg R, Choe DJ, Brown KR, Thaker HM, Singh JR. XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc. Natl. Acad. Sci. U.S.A. 2009; 106: 16351-6.
67. Arnold RS, Makarova NV, Osunkoya AO etal. XMRV infection in patients with prostate cancer: novel serologic assay and correlation with PCR and FISH. Urology 2010; 75: 755-61.
68. Fischer N, Hellwinkel O, Schulz C etal. Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J. Clin. Virol. 2008; 43: 277-83.
69. Verhaegh GW, de Jong AS, Smit FP, Jannik SA, Melchers WJ, Schalken JA. Prevalence of human xenotropic murine leukemia virus-related gammaretrovirus (XMRV) in Dutch prostate cancer patients. Prostate 2011; 71: 415-20.
70. Switzer WM, Jia H, Zheng H, Tang S, Heneine W. No association of xenotropic murine leukemia virus-related viruses with prostate cancer. PLoS ONE 2011; 6: e19065.
71. Stieler K, Schindler S, Schlomm T etal. No detection of XMRV in blood samples and tissue sections from prostate cancer patients in Northern Europe. PLoS ONE 2011; 6: e25592.
72. Aloia AL, Sfanos KS, Isaacs WB etal. XMRV: a new virus in prostate cancer? Cancer Res. 2010; 70: 10028-33.
73. Paprotka T, Delviks-Frankenberry KA, Cingöz O etal. Recombinant origin of the retrovirus XMRV. Science 2011; 333: 97-101.
74. Oakes B, Tai AK, Cingöz O etal. Contamination of human DNA samples with mouse DNA can lead to false detection of XMRV-like sequences. Retrovirology 2010; 7: 109.
75. Sato E, Furuta RA, Miyazawa T. An endogenous murine leukemia viral genome contaminant in commercial RT-PCR kit is amplified using standard primers for XMRV. Retrovirology 2010; 7: 110.
76. De Marzo AM, Platz EA, Sutcliffe S etal. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 2007; 7: 256-69.
77. Wright JL, Neuhouser ML, Lin DW etal. AMACR polymorphisms, dietary intake of red meat and dairy and prostate cancer risk. Prostate 2011; 71: 498-506.
78. Rodriguez C, McCullough ML, Mondul AM etal. Meat consumption among Black and White men and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol. Biomarkers Prev. 2006; 16: 211-16.
79. Sinha R, Park Y, Graubard BI etal. Meat and meat-related compounds and risk of prostate cancer in a large prospective cohort study in the United States. Am. J. Epidemiol. 2009; 170: 1165-77.
80. John EM, Stern MC, Sinha R, Koo J. Meat consumption, cooking practices, meat mutagens, and risk of prostate cancer. Nutr. Cancer 2011; 63: 525-37.
81. Cross AJ, Peters U, Kirsh VA etal. A prospective study of meat and meat mutagens and prostate cancer risk. Cancer Res. 2005; 65: 11779-84.
82. Koutros S, Cross AJ, Sandler DP etal. Meat and meat mutagens and risk of prostate cancer in the Agricultural Health Study. Cancer Epidemiol. Biomarkers Prev. 2008; 17: 80-7.
83. Major JM, Cross AJ, Watters JL, Hollenbeck AR, Graubard BI, Sinha R. Patterns of meat intake and risk of prostate cancer among African-Americans in a large prospective study. Cancer Causes Control 2011; 22: 1691-18.
84. Sander A, Linseisen J, Rohrmann S. Intake of heterocyclic aromatic amines and the risk of prostate cancer in the EPIC-Heidelberg cohort. Cancer Causes Control 2011; 22: 109-14.
85. Shirai T, Sano M, Tamano S etal. The prostate: a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine (PhIP) derived from cooked foods. Cancer Res. 1997; 57: 195-8.
86. Felton JS, Knize MG. Occurrence, identification, and bacterial mutagenicity of heterocyclic amines in cooked food. Mutat. Res. 1991; 259: 205-17.
87. Archer CL, Morse P, Jones RF, Shirai T, Haas GP, Wang CY. Carcinogenicity of the N-hydroxy derivative of 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine, 2-amino-3, 8-dimethyl-imidazo[4, 5-f]quinoxaline and 3, 2′-dimethyl-4-aminobiphenyl in the rat. Cancer Lett. 2000; 155: 55-60.
88. Sugimura T. Mutagens, carcinogens, and tumor promoters in our daily food. Cancer 1982; 49: 1970-84.
89. Puangsombat K, Gadgil P, Houser TA, Hunt MC, Smith JS. Occurrence of heterocyclic amines in cooked meat products. Meat Sci. 2012; 90: 739-46.
90. Schut HA, Snyderwine EG. DNA adducts of heterocyclic amine food mutagens: implications for mutagenesis and carcinogenesis. Carcinogenesis 1999; 20: 353-68.
91. Nakai Y, Nelson WG, De Marzo AM. The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo[4, 5-b]pyridine acts as both a tumor initiator and promoter in the rat ventral prostate. Cancer Res. 2007; 67: 1378-84.
92. Bischoff SC, Lorentz A, Schwengberg S, Weier G, Raab R, Manns MP. Mast cells are an important cellular source of tumour necrosis factor alpha in human intestinal tissue. Gut 1999; 44: 643-52.
93. Lauber SN, Ali S, Gooderham NJ. The cooked food derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4, 5-b] pyridine is a potent oestrogen: a mechanistic basis for its tissue-specific carcinogenicity. Carcinogenesis 2004; 25: 2509-17.
94. Naslund MJ, Strandberg JD, Coffey DS. The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. J. Urol. 1988; 140: 1049-53.
95. Robinette CL. Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate. Prostate 1988; 12: 271-86.
96. Harris MT, Feldberg RS, Lau KM, Lazarus NH, Cochrane DE. Expression of proinflammatory genes during estrogen-induced inflammation of the rat prostate. Prostate 2000; 44: 19-25.
97. Ellem SJ, Wang H, Poutanen M, Risbridger GP. Increased endogenous estrogen synthesis leads to the sequential induction of prostatic inflammation (prostatitis) and prostatic pre-malignancy. Am. J. Pathol. 2009; 175: 1187-99.
98. Nonomura N, Takayama H, Nishimura K etal. Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. Br. J. Cancer 2007; 97: 952-6.
99. Johannson A, Rudolfsson S, Hammarsten P etal. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am. J. Pathol. 2010; 177: 1031-41.
100. Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int. J. Cancer 1998; 77: 511-5.
101. Neugut AI, Rosenberg DJ, Ahsan H etal. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol. Biomarkers Prev. 1998; 7: 869-73.
102. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol. Rep. 2000; 7: 169-70.
103. Langman MJ, Cheng KK, Gilman EA etal. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ. 2000; 320: 1642-6.
104. Perron L, Bairati I, Moore L etal. Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int. J. Cancer 2003; 106: 409-15.
105. Lipworth L, Friis S, Blot WJ etal. A population-based cohort study of mortality among useres of ibuprofen in Denmark. Am. J. ther. 2004; 11: 156-63.
106. García Rodríguez LA, González-Pérez A. Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004; 13: 649-53.
107. Menezes RJ, Swede H, Niles R etal. Regular use of aspirin and prostate cancer risk (United States). Cancer Causes Control 2006; 17: 251-6.
108. Bosetti C, Talamini R, Negri E etal. Aspirin and the risk of prostate cancer. Eur. J. Cancer Prev. 2006; 15: 43-5.
109. Liu X, Plummer SJ, Nock NL etal. Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha. Am. J. Epidemiol. 2006; 164: 984-9.
110. Mahmud SM, Tanguay S, Bégin LR etal. Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population. Eur. J. Cancer Prev. 2006; 15: 158-64.
111. Dasgupta K, Di Cesar D, Ghosn J etal. Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J. 2006; 12: 130-5.
112. Salinas CA, Kwon EM, FitzGerald LM etal. Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am. J. Epidemiol. 2010; 172: 578-90.
113. Mahmud SM, Franco EL, Turner D etal. Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS One 2011; 6: e16412.
114. Paganini-Hill A, Chao A, Ross RK etal. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ. 1989; 299: 1247-50.
115. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994; 5: 138-46.
116. Leitzmann MF, Stampfer MJ, Ma J etal. Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2002; 11: 1108-11.
117. Habel LA, Zhao W, Stanford JL. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 2002; 13: 427-34.
118. Roberts RO, Jacobson DJ, Girman CJ. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo. Clin. Proc. 2002; 77: 219-25.
119. Sørensen HT, Friis S, Nørgård B. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br. J. Cancer 2003; 88: 1687-92.
120. Ratnasinghe LD, Graubard BI, Kahle L etal. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res. 2004; 24: 3177-84.
121. Jacobs EJ, Rodriguez C, Mondul AM etal. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J. Natl. Cancer Inst. 2005; 97: 975-80.
122. Platz EA, Rohrmann S, Pearson JD etal. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol. Biomarkers Prev. 2005; 14: 390-6.
123. Jacobs EJ, Newton CC, Stevens VL etal. A large cohort study of long-term acetaminophen use and prostate cancer incidence. Cancer Epidemiol. Biomarkers Prev. 2011; 20: 1322-8.
124. Dhillon PK, Kenfield SA, Stampfer MJ etal. Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006. Int. J. Cancer 2011; 128: 2444-52.
125. 125Mahmud SM, Franco EL, Aprikian AG. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int. J. Cancer 2010; 127: 1680-91.
126. Olsen JH. Interpretation in drug epidemiology. Lancet 1998; 352: 162-3.